肿瘤免疫：生物创新【研报】

pengxuleo

5 M% J3 j/ w3 e( u2 g2 c, E8 b: K, l( E& s3 f
目录5 R9 b& Y. ?6 h* v- K4 w* x+ x
免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 4" Y, g$ k7 v, K* c1 A. M
抗癌领域新突破 .................................................................................................................. 4
7 Y6 @! K* z0 o# H" G4 {6 F; b600 亿美元市场空间 ............................................................................................................ 4
" ?3 T1 C0 Z8 l. G% r6 ^. U  ]! q免疫检查点的突破——PD-1 ....................................................................................................... 5
8 e8 e; j6 a- ~( [+ k; B$ APD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 5
# ~2 Q6 A: r7 S5 z9 g3 qPD-1 重磅产品频出 ............................................................................................................. 5
: U3 Z; U1 [6 `/ Y2 m+ d在研PD-1 单抗全面开花 ....................................................................................................... 6
* n% O/ [6 ]& r8 V* ^' K+ g4 u/ aPD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 7
+ l- ?) z* }# q4 H& b4 hPD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9
& Z3 u4 [1 n" D* A, W+ uPD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 9: L/ _! E1 [! Z+ k% X, d/ ^
PD-1 市场前景广阔 ........................................................................................................... 105 e1 o8 q" i7 k- r& q
免疫治疗热门靶点——PD-L1 ................................................................................................... 196 w  y/ _( h# L$ z
PD-L1 单抗免疫疗法原理 .................................................................................................... 19/ y' r  b! a3 ~: r' N- n
PD-L1 单抗在研情况 .......................................................................................................... 19
2 q0 R4 Z# s: m/ E2 Y# |PD-L1 联用——多靶点治疗新选择 ......................................................................................... 19
$ U: Z( C$ x) E* p- s' k5 OPD-L1 未来市场 ............................................................................................................... 20
4 [2 v9 t7 z& c" q免疫治疗另一靶点——CTLA-4 .................................................................................................. 21
1 f6 U9 R% ~+ c! y2 p9 A  oCTLA-4 单抗免疫疗法原理 ................................................................................................... 21
) d0 T) c: i- T- a. O( D8 J3 ^CTLA-4 单抗已上市产品 ..................................................................................................... 21
" Z! B0 s( d$ o* R7 k% PCTLA-4 在研产品.............................................................................................................. 22+ I4 O5 V, L& I1 j: v* ]6 ?; N
CTLA-4 的未来，联合用药是出路 .......................................................................................... 233 j3 X" p. e; a  r# T6 o
相关公司简介 ........................................................................................................................ 24
( g5 C! a/ n0 [) _0 A1 Z君实生物 ........................................................................................................................ 24
3 C  A" G4 _' F9 l* g恒瑞医药（确信买入评级） .................................................................................................. 25
( \! s$ O$ o- [! `5 x3 ^' h百时美施贵宝（BMS） ....................................................................................................... 26
' V7 q* `6 W  @- a: X默克（Merck） ................................................................................................................ 27
' B  Y( ^' I9 ?
8 b9 \7 [9 ?& ^
3 L4 r  n$ U% t[hide][/hide]

cantonchn

saberche

好好学习一下

chimo100

谢谢

xiaoheilong

感谢分享！

18351507829

本本9705

xx

FreeCell

看看

yinfuhua

学习。

kblb1983

谢谢分享